Leonard S. Schultz, M.D.; Ronald H. Dietzman, M.D.; George J. Motsay, M.D.; Lloyde Romero, M.D.; Charles Beckman, M.D.; Richard C. Lillehei, M.D., Ph.D.
This content is PDF only. Please click on the PDF icon to access.
Ninety-five patients in clinical cardiogenic shock (Group I: cardiac index, ≤ 2 litre/min·m2 body surface area; systolic blood pressure, ≤ 90 mm Hg) and 20 in impending cardiogenic shock (Group II: cardiac index, ≤ 3.0 litres/min·m2 body surface area; systolic blood pressure, ≤ 90 mm Hg) were studied. Sixty-seven patients in Group I were given massive corticoid treatment (methylprednisolone (M-P), intravenously, mg/kg body weight) as primary therapy, whereas the rest received methylprednisolone with a vasopressor infusion of levarteranol, 4 μg/kg body weight·min. Therapy was either randomly selected or specifically requested by the patient's personal physician. Group II was given intravenous
Schultz LS, Dietzman RH, Motsay GJ, Romero L, Beckman C, Lillehei RC. Clinical Cardiogenic Shock. Vasopressor Versus Corticoid Therapy.. Ann Intern Med. ;76:867–868. doi: 10.7326/0003-4819-76-5-867_5
Download citation file:
Published: Ann Intern Med. 1972;76(5):867-868.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use